Free Trial

Arbutus Biopharma (ABUS) SEC Filings & 10K Form

Arbutus Biopharma logo
$3.22 +0.05 (+1.58%)
Closing price 04:00 PM Eastern
Extended Trading
$3.16 -0.06 (-1.83%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Arbutus Biopharma SEC Filings

DateFilerForm TypeView
05/14/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/07/2025
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/23/2025
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/21/2025
1:11 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2025
3:27 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/01/2025
4:47 PM
Arbutus Biopharma (Issuer)
Nguyen Tuan (Reporting)
Form 4/A
03/31/2025
8:42 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/24/2025
8:19 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2025
3:08 PM
Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2025
3:10 PM
Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2025
8:34 AM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/07/2025
1:59 PM
Arbutus Biopharma (Subject)
Sofia Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/06/2025
3:07 PM
Arbutus Biopharma (Issuer)
Gline Matthew (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:08 PM
Androski Lindsay (Reporting)
Arbutus Biopharma (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:10 PM
Arbutus Biopharma (Issuer)
Beardsley Robert A (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:11 PM
Arbutus Biopharma (Issuer)
Bishop Joseph E (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/06/2025
3:13 PM
Arbutus Biopharma (Issuer)
Hasija Anuj (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/03/2025
8:24 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2025
6:05 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/25/2025
6:19 AM
Arbutus Biopharma (Subject)
Roivant Sciences Ltd. (Filed by)
Roivant Sciences Ltd. (Filed by)
Form SCHEDULE 13D/A
02/21/2025
8:00 AM
Arbutus Biopharma (Subject)
Whitefort Capital Management, LP (Filed by)
Form SCHEDULE 13D/A
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
Sims Karen (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
HASTINGS DAVID C (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
McElhaugh Michael J. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
5:25 PM
Arbutus Biopharma (Issuer)
Naftzger J. Christopher (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/04/2025
7:34 PM
Arbutus Biopharma (Subject)
Naftzger J. Christopher (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:36 PM
Arbutus Biopharma (Subject)
McElhaugh Michael J. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:38 PM
Arbutus Biopharma (Subject)
Sims Karen (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
7:39 PM
Arbutus Biopharma (Subject)
HASTINGS DAVID C (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/03/2025
2:26 PM
Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
Form SCHEDULE 13G/A
01/13/2025
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2024
11:15 PM
Arbutus Biopharma (Filer)
Form EFFECT
11/15/2024
10:03 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
7:41 AM
Arbutus Biopharma (Subject)
Two Seas Capital LP (Filed by)
Form SC 13G/A
11/06/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/15/2024
7:26 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/11/2024
3:07 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
6:31 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2024
3:50 PM
Arbutus Biopharma (Subject)
MORGAN STANLEY (Filed by)
Form SC 13G
AI Meltdown Imminent: Dump These Stocks Now! (Ad)

If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.

Click here to see the details and learn how to prepare for the next AI revolution
06/06/2024
10:16 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/28/2024
3:25 PM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
3:07 PM
Arbutus Biopharma (Issuer)
Torti Frank (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2024
5:00 AM
Arbutus Biopharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ABUS) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners